Parkinson's Disease

A new study exploring the potential of an experimental drug to reduce involuntary movement in Parkinson's sufferers has returned some promising results, with monkeys undergoing treatment exhibiting much improved symptoms thereafter.

Researchers in Japan have turned their eye to pingpong's potential to treat symptoms of Parkinson's disease, with a six-month preliminary study pointing to significant improvements in the participant's ability to carry out a variety of everyday tasks.

A paper is adding weight to the growing hypothesis suggesting the toxic protein clusters that cause Parkinson’s disease first aggregate in the gut before moving to the brain, and deficiency in a certain enzyme may help this mechanism.

Much research into treatments for Parkinson's concentrates on developing therapies that can arrest a slide in dopamine production, and scientists have now uncovered a new path forward in the form of a molecule found to boosts its levels in mice.

When Parkinson’s patients are diagnosed with the condition, there are still many unknowns around how the disease will impact their lives. While it is no crystal ball, a new blood test is offering hope of better patient management.

Inflammation can get out of hand, causing pain and contributing to diseases like Alzheimer’s and diabetes. A molecular “switch” in mice that could effectively turn off that reaction, possibly reversing these conditions and maybe even aging itself.

New research suggests Parkinson's may be present in the brain right from birth, as malfunctioning neurons are always there. Thankfully, a drug that’s already on the market could help prevent the disease from taking hold if caught early enough.

A new study from a team of Brazilian scientists is reporting results from the first randomized, placebo-controlled clinical trial exploring the effect of cannabidiol (CBD) on anxiety, and anxiety-induced tremors, in Parkinson’s patients.

A new study is describing how a particular probiotic bacterium may have the ability to prevent the abnormal accumulation of a protein commonly associated with the neurological damage seen in Parkinson's disease.

The US Food and Drug Administration (FDA) has delivered a Breakthrough Device Designation to a novel eye-tracking technology that claims to offer objective and early diagnosis of Parkinson’s disease. The FDA designation is hoped to accelerate the approval process for the test offering clinicians a new and reliable way to diagnose the degenerative disease at its earliest stage.

A team of Australian researchers has developed a novel early detection test for Parkinson’s disease based on a short series of drawing and writing tasks. The team is aiming to move through final trial stages and bring the new test to market by 2022.

Fascinating research reveals evidence for the first time suggesting deep brain electrical stimulation directly increases dopamine releases in the brain.